A pragmatic trial with an optimized dose of rifampicin and moxifloxacin for the treatment of drug-susceptible pulmonary tuberculosis: a study protocol for open-label, randomized phase III trial (OptiRiMoxTB). - Mlyuka HJ; Liyoyo A; Nyaulingo B; Mpolya E; Kaswaga OL; Semvua H; Lwambura S; McHugh TD; Wildner L; Sabiiti W; Adegbite BR; Nliwasa M; et al. (Trials, 2026)